CENTER VALLEY, Pa., (October 18, 2019) – Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today that Olympus and Ethicon, Inc. have entered an agreement in which Olympus will take over all new commercial activities related to the VERSAPOINT™ Electrosurgery system from Ethicon. With this agreement, Olympus will acquire new channels in its Gynecology Business toward its goal of bringing patients and customers more minimally invasive technology and product options.
For several years Olympus has supplied Gynecare (part of Ethicon) with resectoscopes, generators and electrodes that together comprise the VERSAPOINT Bipolar Electrosurgery System. The VERSAPOINT system is used and trusted by healthcare practitioners worldwide for the treatment of various intrauterine pathologies such as myomas, polyps, intrauterine adhesions and uterine septa. In addition to continuing to manufacture the products, pursuant to the new agreement Olympus will take over all new commercial sales and marketing activities related to VERSAPOINT starting from January 1, 2020. As part of the transaction, Olympus will also acquire the VERSAPOINT trademark. Going forward, the current VERSAPOINT resectoscope will be phased out and replaced with Olympus’ OES Pro 8.5mm resectoscope.
The companies anticipate that Olympus will take over commercial activities in most European countries and the U.S.(*), as well as countries in which only an EU declaration of conformity is required for marketing of VERSAPOINT products, starting from January 1, 2020. Ethicon will continue to provide VERSAPOINT products to customers in certain other territories until applicable regulatory approvals have been obtained, at which point Olympus will take on sales and marketing activities in these countries. Olympus will also offer repair services for the VERSAPOINT generators (subject to local availability). The Versascope hysteroscope does not form part of the agreement and will remain with Ethicon.
Manisha Shah-Bugaj, Global Head of Olympus’ Gynecology Business, commented, “We believe that the VERSAPOINT Electrosurgery system will form an important and highly complementary part of Olympus’ product offering, supporting our strategy of offering best-in-class, minimally invasive treatments to gynecologists. We will continue developing our business to support more customers and patients as a global medtech company.”
A customer letter with further details will be sent to Ethicon customers in respective regions following this announcement.
*The products, while 510(k)-cleared, are not yet authorized for marketing by Olympus in the U.S.
# # #
About Olympus
Since our founding in 1919, Olympus has thrived on our pioneering spirit of innovation, crafting groundbreaking solutions in the medical, scientific, and imaging fields. A global medtech company with more than 35,000 employees in locations in nearly 40 countries, we are committed to helping make people’s lives healthier, safer and more fulfilling around the world.
Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Olympus representative if you have questions about the availability of specific Olympus products in your area.
i Ginsberg GG. Food bolus impaction. Gastroenterol Hepatol (N Y). 2007;3(2):85–86.